Ongoing Clinical Trials for Follicular Lymphoma with Early Relapse
This article provides information about an ongoing clinical trial investigating new treatment options for patients with follicular lymphoma grade I, II, or III who have experienced an early return of the disease. The trial is exploring a bispecific antibody called mosunetuzumab as a second-line treatment option for patients whose lymphoma has relapsed or progressed within 24 months of starting their first treatment. (Also known as: Follicle centre lymphoma follicular grade I II III recurrent)
Clinical trial locations
- Denmark
- Finland
- Norway
- Sweden
Study of Mosunetuzumab for Patients with Early Relapse of Follicular Lymphoma
This clinical trial is investigating mosunetuzumab, a bispecific antibody designed to help the immune system recognize and destroy cancer cells. The study focuses on patients with follicular lymphoma who have experienced an early relapse, meaning their disease has returned or worsened within 24 months after completing their first treatment.
Who can participate:
- Adults aged 18 years or older
- Patients with follicular lymphoma grade 1-3a that has relapsed or progressed within 24 months of starting first treatment, or did not respond to initial treatment
- Patients must have at least one measurable area of cancer with a diameter greater than 15mm
- Patients with a WHO performance status of 0-2, which measures daily activity levels (those with a worse status may be considered if the lymphoma is the cause)
- Participants must provide written informed consent after understanding the trial’s purpose and procedures
Who cannot participate:
- Patients with other types of cancer besides follicular lymphoma
- Patients whose disease did not return or worsen within 24 months after starting their first treatment
- Patients who are not suitable for the specific treatment being tested
- Patients unable to follow study procedures or attend required visits
- Patients with certain medical conditions that might interfere with the treatment
- Pregnant or breastfeeding women
- Patients who have recently participated in another clinical trial
- Patients with a history of severe allergic reactions to similar medications
Trial focus and goals:
The trial aims to evaluate how effective mosunetuzumab is as a second-line treatment for patients with early relapse. The medication is administered as a subcutaneous injection, meaning it is given under the skin rather than through an intravenous line. Treatment consists of 8 cycles, with the medication given at specific intervals according to the trial protocol.
The primary goal is to observe progression-free survival, which is the length of time during and after treatment that the disease does not get worse. Participants will be monitored for up to four years to assess this outcome. The study will also measure the overall response rate, complete response rate, and duration of response to treatment. Some participants may receive a placebo to allow comparison with the active treatment.
Regular monitoring will include imaging tests such as FDG-PET-CT scans to evaluate how the lymphoma responds to treatment. After completing the treatment cycles, further evaluations will determine the overall effectiveness and any changes in the disease.
Investigational drug:
Mosunetuzumab is a monoclonal antibody that works by targeting specific proteins on the surface of cancer cells. This helps the immune system to recognize and destroy these cells more effectively. As a bispecific antibody, it can bind to two different targets simultaneously, making it a unique approach to treating lymphoma. The medication is currently being studied specifically for its effectiveness in cases where follicular lymphoma has returned or worsened after initial treatment.
Summary
Currently, one clinical trial is available for patients with follicular lymphoma who have experienced early relapse. This trial is being conducted across four Nordic countries: Sweden, Denmark, Finland, and Norway, making it accessible to patients throughout Scandinavia. The study represents an important investigation into mosunetuzumab as a potential second-line treatment option for patients whose disease has proven difficult to control with initial therapy. The trial’s focus on early relapse addresses a significant clinical need, as patients whose disease returns within 24 months of first treatment often require alternative therapeutic approaches.